Damon Inc. (Ticker: DMN) is a dynamic player in the healthcare diagnostics sector, specializing in innovative solutions for disease detection and management. With a commitment to enhancing patient outcomes through advanced technology, Damon Inc. leverages its proprietary platforms to develop a range of diagnostic products. The company is strategically positioned to capitalize on the growing demand for accurate and timely diagnostic tools, supported by a robust pipeline of research and development initiatives. As it expands its product offerings and market presence, Damon Inc. aims to establish itself as a leading provider in the rapidly evolving healthcare landscape.
| Revenue (TTM) | 49,520 |
| Gross Profit (TTM) | 28,190 |
| EBITDA | $-8.29M |
| Operating Margin | -6820.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.15 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 84.12 |
| EV/Revenue | 27.04 |
| EV/EBITDA | 0.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.45B |
| Float | $21.47M |
| % Insiders | 2.43% |
| % Institutions | 0.85% |